Lenvima (Lenvatinib Mesylate) Patent Expiration, LOE Window & CMS Spending

Lenvima (Lenvatinib Mesylate) by Eisai: FDA Orange Book core substance LOE 2036-02-26 (last listed 2038-11-15), 0 AB generics, $1.01B 2024 CMS Part D & Medicaid spend, and 48 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEisai
FDA Application & PathwayN206947 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-02-26
Last Listed Patent or Exclusivity Date2038-11-15
Orange Book Patents (*PED Extensions)20 patents (10 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.01B
2024 Medicare Part D Spend$875.6M
2024 Medicaid Spend$135.0M
Reported Wholesale Price Change (CA SB 17)48 WAC filings (max 23.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.